Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and Nε-(carboxymethyl) lysine ELISA

Diabetes Care

Volumn 26, Issue 9, 2003, Pages 2609-2615

  Galler, Angela ^a,d   Müller, Grit ^a   Schinzel, Reinhard ^b   Kratzsch, Juergen ^a   Kiess, Wieland ^a   Münch, Gerald ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Neuroimmunological Cell Biology Unit   (Germany)

^d Children's Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; LIPID METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; SPECTROFLUOROMETRY;

EID: 0041823228     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.9.2609     Document Type: Article

References (27)

1. Ruderman N, Williamson J, Brownlee M (Eds.): Hyperglycemia: Diabetes and Vascular Disease. New York, American Physiological Society, Oxford University Press, 1992
2. King GL, Kunisaki M, Inoguchi T, Shiba T, Xia P: Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 45 (Suppl.3):S105-108, 1996
3. The DCCT Research Group: The effect of intensive diabetes treatment on the development and progression of long term complications in insulin dependent diabetes mellitus: the diabetes control and complications trial. N Engl J Med 329:977-986, 1993
4. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J: Worldwide incidence of type 1 diabetes: the analysis of data on published incidence trends. Diabetologia 42:1395-1403, 1999
5. Karvonen M, Pitkaniemi J, Tuomilehto J, The Finnish Childhood Type 1 Diabetes Registry Group: The onset age of type 1 diabetes in Finnish children has become younger. Diabetes Care 22:1066-1070, 1999
6. Singh R, Barden A, Mori T, Beilin L: Advanced glycation endproducts: a review. Diabetologia 44:129-146, 2001
7. Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Int Med 251:87-101, 2002
8. Sell DR, Monnier VM: End stage renal disease and diabetes catalyse the formation of a pentose-derived cross-link form aging human collagen. J Clin Invest 85:380-384, 1990
9. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oneopoulos D, Diamandis EP: Immunological quantification of AGEs in serum of patients on haemodialysis or peritoneal dialysis. Kidney Int 46:216-222, 1994
10. Makita Z, Radoff S, Rayfield EJ: Advanced glycation end products in diabetic nephropathy. N Engl J Med 325:836-842, 1991
11. Münch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Lemke H, Niwa T, Schinzel R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35:669-677, 1997
12. Soulis T, Thallas V, Youssef S: Advanced glycation end-products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40:619-628, 1997
13. Yoshida S, Yamada K, Hamaguchi K: Immunohistochemical study of human advanced glycation end products (AGE) and growth factors in cardiac tissue of patients on maintenance dialysis and kidney transplantation. Clin Nephrol 49:273-280, 1998
14. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: N (ε)-(carboxymethyl)lsyine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35:8075-8083, 1996
15. Schwedler SB, Metzger T, Schinzel R, Wanner C: Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62:301-310, 2002
16. Berg TJ, Dahl-Jorgensen K, Torjesen PA, Hannssen KF: Increased serum levels of advanced glycation endproducts (AGEs) in children and adolescents with IDDM. Diabetes Care 20:1006-1008, 1997
17. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad H-J, Hannssen KF: The advanced glycation end product Nε-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 21:1997-2002, 1998
18. Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, Verrotti A: Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 134:486-491, 1999
19. Chiarelli F, Catino M, Tumini S, Cipollone F, Mezzetti, Varielli M, Verrotti A: Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr Nephrol 14:841-846, 2000
20. Sebekova K, Podracka L, Blazicek P, Syroya D, Heidland A, Schinzel R: Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 16:1105-1112, 2001
21. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Lui C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474-6479, 1997
22. Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T: Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patient. Mol Med 5:393-405, 1999
23. Baynes JW, Thorpe SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708-1716, 2000
24. Odetti P, Pronzato MA, Noberasco G, Cosso L, Traverso N, Cottalasso D, Marinari UM: Relationships between glycation and oxidation related fluorescences in rat collagen during aging: an in vivo and in vitro study. Lab Invest 70:61-67, 1994
25. Ohgami N, Nagai R, Miyazaki A, Ikemoto M, Arai H, Horiuchi S, Nakayama H: Scavenger receptor class B type 1-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 276:13348-13355, 2001
26. Laffont I, Shuvaev VV, Briand O, Lestavel S, Barbier A, Taniguchi N, Fruchart JC, Clavey V, Siest G: Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochim Biophys Acta 1583:99-107, 2002
27. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9, 1999